Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade.

Rui YangSamah ElsaadiKristine MisundPegah AbdollahiEsten Nymoen VandsembSiv Helen MoenAnna KusnierczykGeir SlupphaugTherese StandalAnders WaageTobias S SlørdahlTorstein Baade RøEven RustadAnders SundanCarl HayZachary A CooperAlwin G SchullerRichard WoessnerAlexandra BorodovskyEline MenuMagne BørsetAnne Marit Sponaas

Published in: Journal for immunotherapy of cancer (2021)

Our data suggest that the adenosine pathway can be successfully targeted in MM and blocking this pathway could be an alternative to PD1/PDL1 inhibition for MM and other hematological cancers. Inhibitors of the adenosine pathway are available. Some are in clinical trials and they could thus reach MM patients fairly rapidly.

Keyphrases

clinical trial
protein kinase
end stage renal disease
multiple myeloma
newly diagnosed
cancer therapy
chronic kidney disease
peritoneal dialysis
electronic health record
young adults
machine learning
big data
drug delivery
nk cells